Tranexamic Acid

CAS No:
1197-18-8 Category:
  • #LGM Pharma is a Tranexamic Acid CAS# 1197-18-8 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 1197-18-8
  • AHFC code: 20:28.2
  • Synonyms: Tranexamsaeure tranexmic acid Tranhexamic acid Trans AMCHA trans-4-aminomethylcyclohexane-1-carboxylic acid trans-Amcha trans-Tranexamic acid
  • ATC Code: B02AA02
  • Chemical Formula: C19H22ClN5O
  • Molecular Weight: 157.2102
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00302 (APRD01270, EXPT00508)
  • SMILES: NC[C,H]1CC[C,,H](CC1)C(O)=O
  • InChl: GYDJEQRTZSCIOI-LJGSYFOKSA-N
  • PubChem: 5526
  • IUPAC: (1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic acid

Additional Details

Indication:
For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.
Pharmacodynamics:
Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).
Mode of Action:
Tranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.
Metabolism:
Only a small fraction of the drug is metabolized (less than 5%).
Toxicity:
Oral LD50 in mice is >10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials